SV-BR-1-GM + Cyclophosphamide + Interferon-alpha-2b
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breastcancer
Conditions
Breastcancer, Breast Neoplasm
Trial Timeline
May 5, 2017 → Nov 22, 2018
NCT ID
NCT03066947About SV-BR-1-GM + Cyclophosphamide + Interferon-alpha-2b
SV-BR-1-GM + Cyclophosphamide + Interferon-alpha-2b is a phase 1/2 stage product being developed by BriaCell Therapeutics for Breastcancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03066947. Target conditions include Breastcancer, Breast Neoplasm.
Hype Score Breakdown
Clinical
9
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03066947 | Phase 1/2 | Completed |
Competing Products
2 competing products in Breastcancer